Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.
Leukemia, Pediatric Leukemia, Pediatrics
Phase II
Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics
Bendamustine, Brentuximab Vedotin, Nivolumab (BMS-936558)
Friedman, Debra
Vanderbilt University


5 Years
Inclusion Criteria:

Classic Hodgkin Lymphoma (cHL), relapsed or refractory

Minimal limitation on activities of daily living as measured by Karnofsky ? 50 for participants > 16 years of age or Lansky ? 50 for participants ? 16 years of age.

One prior anti-cancer therapy that did not work

Exclusion Criteria:

Active, known, or suspected autoimmune disease or infection

Active cerebral/meningeal disease related to the underlying malignancy

More than one line of anti-cancer therapy or no treatment at all

Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant

Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: